|By PR Newswire||
|March 12, 2014 05:16 PM EDT||
CASTLE ROCK, Colo., March 12, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will host a conference call to discuss top-line results from its pivotal study of the APPY1 Test tomorrow, Thursday, March 13, 2014, at 8:30 a.m. ET. The conference call will be hosted by Steve Lundy, Chief Executive Officer.
Interested participants and investors may access the conference call by dialing 1-877-870-4263 (U.S.), 1-855-669-9657 (Canada) or 1-412-317-0790 (international). A live audio webcast will be accessible via the Investor Relations section of the Venaxis web site, ir.venaxis.com.
A telephonic replay of the call will be available for 90 days beginning approximately one hour after the end of the conference call through June 13, 2014. Access numbers for this replay are 1-877-344-7529 (U.S./Canada) and 1-412-317-0088 (international); conference ID: 10042671. The webcast replay will remain available in the Investors Relations section of the Venaxis web site for 90 days.
About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid, protein biomarker-based assay for appendicitis. This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management. The APPY1 Test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging. While FDA clearance is being sought, a commercial launch for the APPY1 Test is ongoing in select European countries. For more information, visit www.venaxis.com.
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial data analysis and related activities for the APPY1 Test required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from the APPY1 Test at a profitable price point, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Form 10-Q for the quarter ended June 30, 2013.
Venaxis and APPY1 are trademarks of Venaxis, Inc.
For Investors and Media:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, PhD
[email protected]; (212) 375-2664
[email protected]; (212) 375-2686
SOURCE Venaxis, Inc.
May. 2, 2016 11:00 PM EDT Reads: 998
May. 2, 2016 08:30 PM EDT Reads: 711
May. 2, 2016 07:45 PM EDT Reads: 1,892
May. 2, 2016 07:00 PM EDT Reads: 1,053
May. 2, 2016 06:30 PM EDT Reads: 1,309
May. 2, 2016 06:00 PM EDT Reads: 719
May. 2, 2016 05:30 PM EDT Reads: 1,569
May. 2, 2016 05:15 PM EDT Reads: 1,001
May. 2, 2016 05:00 PM EDT Reads: 1,102
May. 2, 2016 04:00 PM EDT Reads: 914
May. 2, 2016 03:45 PM EDT Reads: 1,354
May. 2, 2016 03:30 PM EDT Reads: 1,074
May. 2, 2016 03:00 PM EDT Reads: 381
May. 2, 2016 02:45 PM EDT Reads: 1,101